Influenza, Human
Conditions
Keywords
England, Adverse Event of Interest, Seasonal influenza vaccines, Pilot study, Prospective passive enhanced safety surveillance
Brief summary
This pilot study, to be conducted in the 2017/2018 influenza season, is a safety surveillance study using passive surveillance enhanced with a reporting card system to report adverse events of interest (AEIs) after Flu vaccination.
Detailed description
This is the third pilot study following, EPI-FLU-045 VS UK \[NCT02567721\] and EPI-FLU-046 VS UK \[NCT02893878\] studies, carried out in the 2 previous influenza seasons (2015/2016 and 2016/2017). This study will collect data about vaccination status and adverse events following influenza immunisation (AEFI) on a weekly basis, from 01 September 2017 onwards, using a customized Adverse Drug Reaction (ADR) Cards and data from Electronic Health Records system for a period of approximately 13 weeks.
Interventions
OTHEREnhanced vaccine safety surveillance
Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
Sponsors
University of Surrey
GlaxoSmithKline
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
Yes
Inclusion criteria
* All individuals who receive influenza vaccination among the 10 participating GP practices between 1 September and 30 November 2017 are eligible for inclusion in the analysis.
Exclusion criteria
* Registered patients who have explicitly opted out of data sharing will be excluded from the analysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Within 7 days post vaccination | The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea and, vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates expressed as the percentage of subjects, of AEIs were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates expressed as the percentage of subjects, of AEIs were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | The weekly incidence rates expressed as the percentage of subjects, of AEIs were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Within 7 days post vaccination | Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Within 7 days post vaccination | The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card; * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine. Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Within 7 days post vaccination | The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card; * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine. Vaccination of the subjects happened between week 35 and week 48 of the year 2017. |
| Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhoea, nausea and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial oedema and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | SAE data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | Within 7 days post vaccination | SAE data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Within 7 days post vaccination | The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from General Practitioners (GPs). The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhoea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | SAEs reported here are derived from 2 sources of data - ADR cards and SAE routinely collected from GPs. The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any SAEs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhoea, nausea, and vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Within 7 days post vaccination | SAEs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 data sources - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years, and \>65 years. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with seasonal influenza vaccine Vaccination of subjects happened between weeks 35 and 48 of the year 2017 |
| Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 data sources - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12, 13 to 17, 18 to 65, and \>65 years. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of the year 2017 |
| Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported are derived from 2 data sources: ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12, 13 to 17, 18 to 65, and \>65 years. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhea, and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator = the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator = the number of subjects from the denominator who reported any AEIs in EHR (routine data collection + card-based ADR reporting system) within 7 days following vaccination with seasonal influenza vaccine Vaccination happened between weeks 35 and 48, of 2017 |
| Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12, 13 to 17, 18 to 65, and \>65 years. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhea, and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (routine data collection + ADR) within 7 days following vaccination with seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48, 2017 |
| Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhoea, nausea and vomiting. The cumulative incidence rates of AEIs expressed as a cumulative percentage of subjects, were estimated as follows: The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system); The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine. Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 data sources: ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of the year 2017 |
| Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 data sources: ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of 2017 |
| Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of 2017 |
| Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | AEIs reported here are derived from 2 data sources: ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of 2017 |
| Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | SAEs reported here are derived from 2 sources of data - ADR cards and SAEs routinely collected from GPs. SAE data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | Within 7 days post vaccination | SAEs reported here are derived from 2 sources of data - ADR cards and SAEs routinely collected from GPs. SAE data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | SAEs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any SAEs in EHR (combining routine data collection and card-based ADR reporting system)within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
| Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Within 7 days post vaccination | SAEs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any SAEs in EHR (combining routine data collection and card-based ADR reporting system) Vaccination of the subjects happened between week 35 and week 48 of the year 2017 |
Countries
United Kingdom
Participant flow
Pre-assignment details
One study General Practitioner (GP2) did not follow the procedure as per protocol in distributing, handling of the returned cards and the unused Adverse Drug Reaction (ADR) cards, therefore the data from that GP were excluded from the analysis.
Participants by arm
| Arm | Count |
|---|---|
| Vaccinated_Fluarix Tetra Group Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in 10 volunteer GP practices between 01 September and 30 November 2017 | 16,433 |
| Vaccinated_Non GSK Group Volunteered subjects who received non-GSK influenza vaccination in 10 volunteer GP practices between 01 September and 30 November 2017 | 3,310 |
| Vaccinated_Unknown Brand Group Volunteered subjects who received influenza vaccination (GSK or non-GSK brand not known) in 10 volunteer GP practices between 01 September and 30 November 2017 | 4,196 |
| Total | 23,939 |
Baseline characteristics
| Characteristic | Vaccinated_Fluarix Tetra Group | Vaccinated_Non GSK Group | Vaccinated_Unknown Brand Group | Total |
|---|---|---|---|---|
| Age, Continuous | 65.9 Years STANDARD_DEVIATION 16.3 | 23.6 Years STANDARD_DEVIATION 27.4 | 52.2 Years STANDARD_DEVIATION 28 | 57.67 Years STANDARD_DEVIATION 25.21 |
| Race/Ethnicity, Customized Asian | 393 Participants | 63 Participants | 98 Participants | 554 Participants |
| Race/Ethnicity, Customized Black | 84 Participants | 26 Participants | 17 Participants | 127 Participants |
| Race/Ethnicity, Customized Missing | 4177 Participants | 1076 Participants | 1163 Participants | 6416 Participants |
| Race/Ethnicity, Customized Mixed | 57 Participants | 21 Participants | 23 Participants | 101 Participants |
| Race/Ethnicity, Customized Other | 25 Participants | 3 Participants | 15 Participants | 43 Participants |
| Race/Ethnicity, Customized White | 11697 Participants | 2121 Participants | 2880 Participants | 16698 Participants |
| Sex: Female, Male Female | 9177 Participants | 1696 Participants | 2330 Participants | 13203 Participants |
| Sex: Female, Male Male | 7256 Participants | 1614 Participants | 1866 Participants | 10736 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 16,433 | 0 / 3,310 | 0 / 4,196 |
| other Total, other adverse events | 1,514 / 16,433 | 133 / 3,310 | 66 / 4,196 |
| serious Total, serious adverse events | 25 / 16,433 | 3 / 3,310 | 10 / 4,196 |
Outcome results
Primary
Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 6.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 10.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 9.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 8.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 2.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 8.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 8.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 8.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 2.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 7.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 7.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 7.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 2.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 7.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 7.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 6.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 7.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 2.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 2.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 1.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 1.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 3.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 9.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 8.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 8.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 3.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 8.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 7.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 7.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 2.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 7.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 7.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 7.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 2.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 7.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 2.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 4.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 3.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 1.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 2.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 12.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 1.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 1.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 9.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 1.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 1.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 3.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 4.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 5.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 1.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 5.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 3.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 2.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 5.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 1.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 5.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 1.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 6.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 6.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 4.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 6.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 1.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 4.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 6.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 5.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 5.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 4.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 4.84 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 3.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 2.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 1.71 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 4.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 1.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 7.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 7.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 1.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 3.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 22.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 13.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 10.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 6.90 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 5.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 4.65 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 3.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 3.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 4.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 3.42 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 3.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 10.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 8.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 6.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 7.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 7.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 6.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 4.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 4.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 4.30 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 4.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group
The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-45 | 7.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-40 | 8.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-47 | 7.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-43 | 7.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-41 | 8.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-46 | 7.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-37 | 10.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-42 | 7.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-39 | 8.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-48 | 7.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-38 | 8.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-44 | 7.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-39 | 0.95 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-45 | 2.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-38 | 9.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-46 | 2.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-47 | 2.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-48 | 2.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-44 | 2.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-40 | 3.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-41 | 3.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-42 | 2.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-43 | 2.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-48 | 2.01 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-39 | 8.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-37 | 10.53 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-38 | 11.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-40 | 5.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-41 | 4.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-42 | 3.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-43 | 3.24 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-44 | 2.79 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-45 | 2.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-46 | 2.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-47 | 2.05 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group | Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 7.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 8.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 12.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 7.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 11.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 7.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 9.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 8.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 8.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 9.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 8.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 8.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 7.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 8.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 7.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 7.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 8.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 10.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 8.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 8.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 10.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 7.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 7.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 7.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 3.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 3.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 3.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 3.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 2.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 2.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 2.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 9.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 2.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 2.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 2.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 1.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 4.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 3.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 3.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 3.62 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 2.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 7.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 5.77 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 3.80 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 3.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 3.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 2.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 1.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 1.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 50.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 28.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 18.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 4.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 4.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 2.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 2.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 2.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 2.78 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 1.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 1.53 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 28.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 6.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 6.06 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.84 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 1.02 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 1.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 1.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 1.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.72 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group
Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-44 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-38 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-45 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-46 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-47 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-39 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-48 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-40 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-41 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-42 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-37 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-43 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-44 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-42 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-40 | 0.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-45 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-46 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-47 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-43 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-41 | 0.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-48 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-48 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-45 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-46 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-47 | 0.19 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.84 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.97 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.38 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 1.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 1.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 1.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 1.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 1.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 1.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 1.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 1.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 1.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 1.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 1.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 2.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 2.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.74 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 12.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 9.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 1.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 1.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 1.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 1.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 1.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 1.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 2.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 2.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 11.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 6.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 5.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 1.79 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.98 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.40 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group
Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea and, vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 1.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 1.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 2.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 1.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 1.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 1.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 1.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 1.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 1.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 1.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 9.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.95 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 1.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 5.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 2.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 1.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 1.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.42 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.37 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 1.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 1.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 1.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 1.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 1.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 1.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 1.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 1.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 1.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 2.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 2.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 2.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 1.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 2.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 1.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 9.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.98 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.93 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.84 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 2.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 25.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 14.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 3.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 9.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 14.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 3.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 2.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.77 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 3.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 2.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 2.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 2.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 2.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 2.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 2.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 2.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 2.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 2.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 2.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 2.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 3.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 3.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 2.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 3.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 3.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 3.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 2.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 3.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 3.98 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 2.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 4.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 2.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 2.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 1.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.96 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 2.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 1.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 2.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 2.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 2.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 2.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 2.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 1.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 2.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 2.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 2.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 2.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 2.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 2.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 1.94 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 1.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 2.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 1.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 2.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 2.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 11.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 6.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 5.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 1.79 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 1.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.98 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 1.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 1.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 1.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 2.70 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.40 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group
General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 2.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-48 | 1.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-37 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-48 | 0.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-38 | 0.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 2.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-39 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-48 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-40 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-47 | 0.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-41 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-42 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-43 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-42 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-44 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 2.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-45 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 2.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-46 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-47 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-48 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-37 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-38 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 2.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-39 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-40 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-44 | 1.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-41 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-42 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-37 | 2.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-43 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-44 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-47 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-45 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-46 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 2.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-38 | 1.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-40 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-39 | 1.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-40 | 1.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-41 | 1.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-41 | 0.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 3.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-43 | 1.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 2.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-44 | 1.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 2.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-45 | 1.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-42 | 0.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-37 | 1.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-46 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-47 | 1.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-43 | 0.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-38 | 0.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 3.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-48 | 1.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 3.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-39 | 0.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-37 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-38 | 1.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 3.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-39 | 1.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-40 | 1.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-44 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-41 | 1.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-42 | 1.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-45 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-43 | 1.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-45 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-46 | 0.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-46 | 1.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-47 | 1.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-47 | 0.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-44 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-48 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-46 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-40 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-41 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-40 | 0.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.91 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-47 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-41 | 0.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-42 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-44 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-43 | 0.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 1.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-43 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-44 | 0.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-41 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-45 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-44 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-46 | 0.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-47 | 0.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-48 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-42 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-48 | 0.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-45 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-46 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-45 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-46 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-47 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 1.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-43 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-40 | 0.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-45 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-48 | 0.34 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 3.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-44 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 5.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 2.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 2.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 1.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 1.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 1.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.93 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-37 | 5.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-38 | 2.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-39 | 1.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-40 | 1.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-41 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-42 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-43 | 0.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-45 | 0.42 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-46 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-47 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-48 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-39 | 1.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-40 | 1.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-41 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-42 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-43 | 0.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-44 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-45 | 0.42 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-46 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-47 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-48 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-47 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 3.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 2.84 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 2.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 2.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 2.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 4.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 2.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 2.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 2.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 3.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 2.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 3.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 2.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 2.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 2.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 3.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 3.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 3.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 2.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 3.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 2.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 3.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 2.99 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 4.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.95 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 1.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 1.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 1.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 1.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 14.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.87 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.77 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 14.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 9.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 3.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 3.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 2.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.58 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 2.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 25.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.77 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.38 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 1.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 3.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 2.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 1.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 2.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 1.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 1.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 1.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 1.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 1.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 2.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 1.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 2.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 2.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 2.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 1.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 1.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 1.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 2.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 3.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 2.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 2.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 1.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 1.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 1.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 1.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 1.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 1.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 2.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 1.94 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 6.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 11.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 2.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 2.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 1.79 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.98 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 5.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group
Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-44 | 1.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-45 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-46 | 1.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-39 | 1.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-47 | 1.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-48 | 1.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-42 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-40 | 1.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-37 | 1.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-41 | 1.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-43 | 1.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-38 | 1.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-42 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-45 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-40 | 0.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-46 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-43 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-44 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-47 | 0.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-41 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-48 | 0.58 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-48 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-37 | 5.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-38 | 2.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-39 | 1.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-40 | 1.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-41 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-42 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-43 | 0.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-44 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-45 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-46 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-47 | 0.19 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 3.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 5.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 5.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 1.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 3.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 1.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 1.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 1.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 3.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 1.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 3.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 3.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 1.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 1.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 3.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 3.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 1.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 4.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 3.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 4.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 1.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 1.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 1.01 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 14.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 14.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 9.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 3.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 25.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 3.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 2.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 2.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 3.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 2.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 2.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 2.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 2.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 2.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 2.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 2.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 2.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 2.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 2.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 2.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 2.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 2.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 2.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 2.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 2.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 3.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 3.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 2.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 2.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 4.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 3.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 4.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.80 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 1.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 1.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 1.02 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 1.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 1.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 1.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 5.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 2.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 2.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 3.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 2.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 1.79 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 4.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 11.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 6.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 3.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 3.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.98 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 2.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 3.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 2.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 2.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 5.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 5.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.40 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group
Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 2.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 2.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 3.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 2.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 2.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 2.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 2.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 3.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 2.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 2.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 2.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 2.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 0.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 5.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 5.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 2.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 1.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.84 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.81 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 5.71 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 3.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 1.84 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 1.62 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.75 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 4.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 2.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 3.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 6.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 2.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 3.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 2.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 2.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 3.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 2.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 2.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 3.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 3.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 3.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 2.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 3.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 2.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 3.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 4.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 2.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 3.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 4.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 2.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 3.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 1.74 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 14.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 2.53 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 1.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 14.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 25.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 9.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 3.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 3.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 3.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 3.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 2.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 2.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.87 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.93 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 1.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.77 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.74 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 1.39 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 1.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 1.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 1.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 1.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 1.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 1.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group
Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 0.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.19 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.28 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.87 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.77 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.58 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group
The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-42 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-41 | 0.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-43 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-44 | 0.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-45 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-46 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-48 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-47 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-40 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-37 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-38 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-39 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-42 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-43 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-48 | 0.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-44 | 0.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-45 | 0.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-47 | 0.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-41 | 0.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-46 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-45 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 3.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 3.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 3.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 3.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 3.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 4.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 3.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 5.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 4.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 4.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 3.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 4.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 4.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 4.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 3.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 4.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 2.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 2.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 2.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 2.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 4.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 2.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 2.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 2.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 2.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 1.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 4.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 1.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 4.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 5.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 4.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 4.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 4.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 4.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 4.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 3.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 1.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 2.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 1.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 2.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 1.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 2.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 1.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.96 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 2.93 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 1.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 1.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 3.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 2.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 1.02 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 2.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 1.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 2.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 2.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 3.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 3.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 12.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 9.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 3.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 1.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 4.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 7.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 2.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 1.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 3.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 2.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 2.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.0 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 2.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 3.02 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 1.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 1.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.0 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 2.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.96 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 1.71 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 1.65 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 5.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 2.70 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 2.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 1.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 1.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 1.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 1.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 1.08 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group
Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 3.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 4.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 4.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 5.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 4.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 4.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 4.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 4.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 4.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 3.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 4.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 3.93 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 1.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 1.78 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 2.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 1.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 1.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 1.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 2.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 9.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 1.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 1.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.95 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 1.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 1.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 1.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 1.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 1.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 1.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 2.86 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 6.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 3.99 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 5.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 4.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 5.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 4.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 4.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 4.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 4.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 4.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 4.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 4.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 4.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 4.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 4.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 8.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 4.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 4.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 3.93 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 3.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 5.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 3.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 4.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 6.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 1.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 1.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 2.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 1.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 9.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 1.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 1.78 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 1.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 2.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 1.71 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 1.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 1.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 1.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 1.59 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 1.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.87 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 3.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.77 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.58 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 1.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 1.82 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group
SAE data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group
The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card; * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine. Vaccination of the subjects happened between week 35 and week 48 of the year 2017.
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-47 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35- 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35- 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.80 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 1.01 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.96 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.98 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35- 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group
Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates expressed as the percentage of subjects, of AEIs were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 0.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-46 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-45 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-47 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-48 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-40 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35-35 | — Percentage of subjects |
Primary
Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start, up to end of the week of interest and were registered in EHR, using card-based ADR reporting system during the safety FU period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 1.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.36 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group
The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 47 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 45 | 3.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 37 | 10.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 38 | 7.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 39 | 7.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 40 | 8.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 41 | 6.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 42 | 3.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 43 | 4.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 44 | 4.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 46 | 4.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 38 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 43 | 2.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 41 | 3.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 45 | 2.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 40 | 4.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 46 | 1.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 47 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 42 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 44 | 3.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 38 | 12.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 39 | 4.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 41 | 1.79 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 45 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 37 | 12.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any Adverse Events of Interest (AEIs) Reported Via Adverse Drug Reaction (ADR) Card, by Vaccine Group | Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 40 | 8.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 41 | 4.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 42 | 3.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 43 | 4.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 44 | 3.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 10.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 7.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 7.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 8.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 7.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 3.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 5.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 33.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 4.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 7.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 45 | 2.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 46 | 4.93 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 47 | 2.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 37 | 9.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 3.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 38 | 7.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 4.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 39 | 8.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 1.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 40 | 6.78 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 16.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 41 | 4.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 3.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 43 | 6.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 44 | 8.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 7.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 45 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 3.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 46 | 8.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 1.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 16.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 6.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 6.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 3.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 11.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 37 | 22.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 45 | 5.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 20.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 5.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 33.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine and Age Group | 18-65 years, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status
The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 41 | 6.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 45 | 3.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 39 | 7.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 40 | 9.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 46 | 2.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 39 | 10.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 38 | 9.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 47 | 1.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 47 | 2.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 37 | 12.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 40 | 8.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 37 | 9.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 46 | 9.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 41 | 6.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 38 | 7.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 45 | 4.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 42 | 4.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 44 | 4.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 43 | 3.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 43 | 4.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 44 | 4.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 42 | 1.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 38 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 40 | 5.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 41 | 3.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 43 | 2.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 44 | 2.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 45 | 2.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 46 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 47 | 0.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 43 | 5.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 44 | 9.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 45 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 46 | 8.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 39 | 4.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 38 | 15.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 41 | 2.78 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 45 | 2.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 37 | 50.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Reported Via ADR Card, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 1.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 2.53 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.49 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group
Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 39 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 46 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 47 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 40 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 37 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 41 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 43 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 38 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 40 | 1.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 41 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 1.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 1.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 1.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhoea, nausea and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 1.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 1.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 1.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 2.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 1.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 1.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 1.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 1.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 2.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 16.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.28 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 11.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.49 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group
Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 1.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 1.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 1.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 2.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 1.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 1.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 1.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 2.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 1.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 2.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 1.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 2.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 1.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 1.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 1.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 25.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 1.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 3.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 3.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 3.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 2.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 1.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 2.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 2.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 2.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 2.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 3.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 2.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 5.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 2.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 2.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 9.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 1.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 5.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 2.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 4.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.49 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 11.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 5.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group
General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 45 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 1.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 46 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 37 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 38 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 39 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 40 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 2.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 41 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 42 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 43 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 43 | 1.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 45 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 37 | 1.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 37 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 38 | 0.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 39 | 0.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 41 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 42 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 43 | 0.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 40 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 45 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 3.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 37 | 2.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 38 | 1.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 2.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 39 | 1.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 40 | 1.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 41 | 0.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 41 | 1.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 42 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 43 | 0.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 2.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 44 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 45 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 46 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 1.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 44 | 1.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 37 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 38 | 1.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 39 | 1.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 1.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 40 | 1.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 42 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 1.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 41 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 43 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 1.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 44 | 0.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 46 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 41 | 0.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 43 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 45 | 0.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 46 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 44 | 0.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 1.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 45 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 40 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 1.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 40 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 40 | 0.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 41 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 4.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 37 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 39 | 4.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Irritability, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Headache, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Any, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Fatigue, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Drowsiness, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group | Malaise, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 3.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 1.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 4.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 2.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 2.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 1.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 2.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 1.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 3.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 1.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 4.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 2.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 2.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 1.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 1.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 1.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 3.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 2.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 25.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 4.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 2.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 1.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 2.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 3.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 1.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 3.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 1.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 2.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 1.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 3.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 4.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 1.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 3.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 5.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 11.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group
Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 38 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 39 | 1.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 43 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 42 | 0.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 40 | 1.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 47 | 1.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 41 | 1.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 46 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 37 | 1.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 44 | 1.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 46 | 1.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 40 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 41 | 0.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 42 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 43 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 44 | 0.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 45 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 37 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group | Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 5.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 4.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 1.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 2.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 1.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 3.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 1.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 3.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 4.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 6.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 1.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 1.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 5.71 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 25.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 2.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 2.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 3.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 2.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 4.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 1.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 1.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 2.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 3.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 2.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 1.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 2.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 1.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 2.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 5.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 3.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 3.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 10.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 5.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.49 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 11.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group
Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 3.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 2.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 1.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 1.99 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 2.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 2.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 1.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 1.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 4.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 3.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 1.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 4.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 3.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 2.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 2.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 1.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 2.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 2.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 6.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 3.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 2.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 4.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 4.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 1.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 2.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 7.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 4.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 25.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 33.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group
Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 1.79 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 2.78 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group
The weekly incidence rates expressed as the percentage of subjects, of AEIs were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 43 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 44 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 41 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 37 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 38 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 46 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 40 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 39 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 41 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group | Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 1.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 1.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 1.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 2.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 1.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 5.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 4.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 4.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 5.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 3.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 2.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 1.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 3.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 3.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 33.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 7.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 5.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 3.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 4.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 2.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 1.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 5.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 9.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 2.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 2.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 6.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 1.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 3.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 11.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 16.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 8.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 3.80 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 1.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 1.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 5.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 10.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group
Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 2.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 1.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 4.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 5.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 4.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 3.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 2.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 3.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 2.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 2.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 2.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 2.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 1.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 1.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 4.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 3.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 4.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 1.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 4.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 3.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 3.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 2.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 2.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 2.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 1.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 2.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 5.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 3.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 8.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 4.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 6.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 3.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 3.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 1.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 2.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 3.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 5.71 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 1.95 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 2.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 7.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 2.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group
The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card; * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine. Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Reported Via ADR Card by Vaccine Group | Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group
AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial oedema and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 3.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 2.94 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group
Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates expressed as the percentage of subjects, of AEIs were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 45 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group | Any, Week 35 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status
Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 1.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 1.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 3.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.46 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Reported Via ADR Card, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | — Percentage of subjects |
Primary
Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group
SAE data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any SAEs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in electronic health record (EHR), using card-based ADR reporting system during the safety follow-up (FU) period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 37 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | >65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Serious Adverse Events (SAEs) Reported Via ADR Card, by Vaccine and Age Group | 18 - 65 years, Week 36 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 6.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-37 | 11.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 3.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 5.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-44 | 9.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 3.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 5.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 3.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 7.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-48 | 9.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 3.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 7.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-48 | 9.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 2.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 8.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-47 | 9.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 8.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 8.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-43 | 9.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-46 | 9.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-42 | 9.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-45 | 9.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-41 | 9.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-43 | 10.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-40 | 10.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-42 | 10.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-38 | 11.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-41 | 10.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-47 | 9.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-40 | 11.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-46 | 9.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-39 | 11.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-46 | 10.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-37 | 11.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 2.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-47 | 10.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-39 | 10.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 2.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-48 | 10.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-44 | 9.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-45 | 9.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 3.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-38 | 10.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 2.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-46 | 2.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-39 | 5.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-40 | 10.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-44 | 8.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-41 | 8.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-39 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-40 | 4.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-41 | 4.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-42 | 3.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-43 | 3.02 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-44 | 3.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-45 | 2.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-47 | 2.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-48 | 2.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 9.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 5.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 4.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 3.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 2.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 2.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 1.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 1.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 1.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 7.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 6.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 4.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 3.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 2.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 3.01 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 2.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 2.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 2.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-41 | 8.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-42 | 5.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-43 | 6.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-45 | 7.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-46 | 7.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-47 | 7.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-48 | 7.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-38 | 11.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-39 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-40 | 6.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-42 | 7.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-43 | 7.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-44 | 7.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-45 | 8.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-46 | 8.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-47 | 8.02 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-48 | 8.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 3.89 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-37 | 2.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 3.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-48 | 0.70 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-47 | 0.71 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 3.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-46 | 0.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-40 | 1.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 3.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-38 | 1.53 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-45 | 0.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-39 | 1.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-44 | 0.87 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-40 | 1.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-43 | 2.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-47 | 1.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-41 | 1.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-42 | 1.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-42 | 1.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-42 | 1.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-46 | 1.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-45 | 1.81 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-43 | 1.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-46 | 1.74 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-47 | 1.74 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-41 | 1.62 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-44 | 1.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-36 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-48 | 1.70 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.28 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-37 | 0.81 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-44 | 1.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 33.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-48 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 2.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-38 | 1.34 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 2.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-43 | 1.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 2.78 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-45 | 1.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 2.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Weeks 35-39 | 1.85 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Weeks 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-44 | 9.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-40 | 10.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-37 | 11.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-43 | 9.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-41 | 10.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-42 | 9.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-46 | 9.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-38 | 10.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-48 | 9.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-45 | 9.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-39 | 10.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-47 | 9.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-47 | 3.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-38 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-39 | 2.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-40 | 6.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-41 | 5.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-42 | 4.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-43 | 4.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-44 | 4.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-45 | 4.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-46 | 4.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-48 | 4.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-39 | 1.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-47 | 1.59 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-44 | 1.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-38 | 1.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-45 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-37 | 1.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-48 | 1.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-41 | 1.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-46 | 1.59 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-42 | 1.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-40 | 1.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-36 | 1.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group | Week 35-43 | 1.49 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 10.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 13.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 9.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 10.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 13.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 10.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 10.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 12.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 9.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 11.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 10.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 11.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 11.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 9.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 9.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 9.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 9.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 9.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 10.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 10.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 15.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 10.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 14.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 9.95 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 4.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 6.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 4.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 4.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 3.80 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 4.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 3.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 2.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 3.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 5.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 4.84 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 5.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 5.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 7.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 2.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 6.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 3.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 3.83 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 5.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 1.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 2.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 1.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 2.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.80 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 1.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 1.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.59 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 1.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 1.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 1.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 1.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 1.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 1.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 1.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 1.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 1.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 1.72 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 2.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 2.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 3.95 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 1.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 2.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 9.09 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 data sources - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12, 13 to 17, 18 to 65, and \>65 years. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 1.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 2.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 1.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.80 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 1.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.78 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.71 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.64 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group
subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-39 | 0.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-40 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-47 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-41 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-37 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-46 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-42 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-48 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-43 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-45 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-38 | 0.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-45 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-46 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-47 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-48 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-40 | 1.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-41 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-42 | 0.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-43 | 0.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-48 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-43 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-46 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-47 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35-35 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 1.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 1.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.83 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.95 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 1.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhoea, nausea and vomiting. The cumulative incidence rates of AEIs expressed as a cumulative percentage of subjects, were estimated as follows: The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system); The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine. Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 1.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 1.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 1.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 1.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 1.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 1.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 1.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 1.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 1.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 1.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 1.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 2.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.74 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 11.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 1.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 2.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 1.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 1.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 1.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 1.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 1.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.74 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 1.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.62 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.05 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhoea, nausea, and vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who received the ADR card * The numerator was the number of subjects from the denominator who reported any AEIs on the ADR card within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-44 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-41 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-39 | 0.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-45 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 1.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-38 | 1.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-46 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 1.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-37 | 0.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-47 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-40 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-48 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-48 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-47 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-48 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-46 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-37 | 0.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-39 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-45 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-38 | 0.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-44 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-39 | 0.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-45 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-43 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-40 | 0.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-38 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-42 | 0.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-41 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 1.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-37 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 1.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-47 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 1.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-44 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-48 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-47 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-37 | 0.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 2.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-46 | 0.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-38 | 0.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-43 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-45 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-39 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 1.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-44 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-40 | 0.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-43 | 0.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-41 | 0.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-42 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-42 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-42 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-41 | 0.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-43 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-46 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-40 | 0.84 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-45 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 1.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-40 | 0.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-41 | 0.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-42 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-43 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-44 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-45 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-46 | 0.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-47 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-48 | 0.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-44 | 0.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-46 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-47 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-48 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-38 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-39 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-41 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-42 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-43 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-46 | 0.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-47 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-48 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-41 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-42 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-43 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-44 | 0.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-45 | 0.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-46 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-47 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-48 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-46 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-47 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-48 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-48 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-47 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-43 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-44 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-37 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-45 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-46 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-47 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35-48 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35-38 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 1.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 1.84 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 1.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 1.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 1.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 1.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 1.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 1.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 1.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 1.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 1.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 1.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 1.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 2.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 1.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 2.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 2.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 1.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 2.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.91 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 7.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 3.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 3.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 4.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 3.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 3.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 3.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 4.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 3.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 3.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 3.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 3.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 3.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 3.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 3.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 2.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 2.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 2.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 2.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 2.84 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 2.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 2.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 3.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 3.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 3.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 1.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 5.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 5.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 3.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 2.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 2.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 3.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 2.98 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 3.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 2.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 2.74 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 3.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 2.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 2.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 2.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 2.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 2.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 2.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 2.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 2.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 2.78 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.53 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.53 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.62 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 3.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-47 | 1.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-47 | 0.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-43 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-46 | 1.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-48 | 0.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-40 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-45 | 1.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 3.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 3.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-44 | 1.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-37 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-46 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-43 | 1.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-38 | 2.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-38 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-42 | 1.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-39 | 1.93 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 2.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-41 | 1.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-40 | 1.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-37 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-40 | 1.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-41 | 1.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 2.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-39 | 2.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-42 | 1.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 4.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-38 | 2.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-43 | 1.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-48 | 0.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-37 | 2.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-44 | 1.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 2.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-45 | 1.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-48 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-48 | 1.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-46 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-47 | 0.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-47 | 1.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 2.84 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-45 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-46 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 2.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 3.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-45 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-44 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-43 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-37 | 1.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-44 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-42 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-38 | 0.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 3.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-41 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-39 | 0.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-39 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-40 | 0.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-40 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-43 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-41 | 0.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-47 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-39 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-42 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-42 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-38 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 3.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-37 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-44 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-45 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-41 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-48 | 1.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-46 | 0.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-44 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 1.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-47 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 1.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 1.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 1.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 1.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 1.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 1.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 1.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-41 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-43 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-45 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-46 | 0.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-47 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-48 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-40 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-41 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-43 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-44 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-45 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-46 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-47 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-48 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-39 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-40 | 1.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-41 | 1.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-42 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-43 | 0.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-45 | 0.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-46 | 0.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-47 | 0.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-48 | 0.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-42 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-43 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-44 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-45 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-46 | 0.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-48 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-41 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-42 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-43 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-45 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-46 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-47 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-48 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-46 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-47 | 0.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-48 | 0.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-46 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-47 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-44 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-43 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-42 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-41 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-40 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-39 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-37 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-43 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35-45 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35-47 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 2.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 3.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 4.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 2.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 3.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 3.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 2.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 3.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 4.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 2.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 3.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 2.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 3.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 3.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 3.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 3.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 3.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 3.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 3.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 2.99 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 4.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 2.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 3.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 4.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.91 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 2.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 1.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 1.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 1.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 1.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 1.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 1.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 1.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 1.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 1.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 1.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.95 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 3.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.96 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 1.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.88 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 1.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 2.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 1.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 1.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 1.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 2.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 2.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 1.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 2.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 2.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 1.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 3.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 1.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 3.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 1.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 1.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 1.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 2.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 2.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 1.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 1.91 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 1.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 1.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 1.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 1.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 1.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 2.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 2.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.62 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-44 | 1.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-45 | 1.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-39 | 1.84 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-46 | 1.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-47 | 1.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-37 | 1.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-48 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-40 | 1.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-41 | 1.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-42 | 1.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-38 | 1.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-43 | 1.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-45 | 0.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-44 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-41 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-46 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-47 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-43 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-48 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-48 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-37 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-43 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-47 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35-35 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Local symptoms include local erythema. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 3.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 1.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 3.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 5.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 1.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 3.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 1.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 3.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 1.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 3.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 3.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 4.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 1.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 4.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 1.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 3.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 1.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 1.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 3.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 5.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 1.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.84 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 3.03 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 3.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 3.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 1.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 2.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 3.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 3.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 2.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 3.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 3.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 2.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 3.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 3.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 3.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 4.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 3.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 4.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 2.99 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 4.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 2.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 5.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 3.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 2.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 3.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 3.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 2.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 1.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 1.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 1.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 1.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 3.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 1.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 1.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 1.49 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.62 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.42 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.42 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-48 | 2.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-41 | 2.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-42 | 2.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 3.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-38 | 3.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-48 | 0.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 4.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-37 | 1.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 3.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 3.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-38 | 1.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 3.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-39 | 1.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-39 | 3.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-44 | 2.84 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-40 | 1.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 3.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 3.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-41 | 0.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 3.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-45 | 2.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-42 | 0.93 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-37 | 3.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-40 | 3.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-43 | 0.93 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-46 | 2.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 3.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-44 | 0.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-45 | 0.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-47 | 2.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 3.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-46 | 0.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-43 | 2.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 3.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-47 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 3.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-47 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-48 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-40 | 0.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-41 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-43 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-44 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-45 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-46 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-47 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-48 | 0.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-40 | 0.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-41 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-42 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-43 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-44 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-45 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-46 | 0.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-48 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.44 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-43 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-47 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35-48 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-37 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-38 | 0.28 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-39 | 0.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-40 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-41 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-42 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-43 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-44 | 0.34 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-45 | 0.34 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-46 | 0.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Myalgia, Week 35-47 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 3.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 4.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 3.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 4.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 4.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 3.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 4.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 3.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 3.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 3.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 3.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 3.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 3.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 3.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 3.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 3.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 3.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 4.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 2.99 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 3.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 6.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 5.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 3.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 4.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.95 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.30 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.42 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.34 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 15.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 data sources: ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-40 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-44 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-43 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-43 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-41 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-40 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-39 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-37 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-38 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-39 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-39 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-44 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-40 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-42 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-41 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-42 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-38 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-43 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-45 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-44 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-42 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-45 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-37 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-46 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-46 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-48 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-47 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-41 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-47 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-48 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-46 | 0.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-45 | 0.01 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-42 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-43 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-46 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-47 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-48 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-47 | 0.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-48 | 0.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-41 | 0.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-48 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-47 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-43 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure / Febrile convulsions, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35-44 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.64 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-44 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-37 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-38 | 0.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-46 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-39 | 0.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-45 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-43 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-48 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-42 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-41 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-40 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-47 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-48 | 0.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-47 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-41 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-43 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-45 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-46 | 0.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-40 | 0.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-43 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-41 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-47 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-46 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-38 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-39 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-42 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Week 35-44 | 0.09 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 2.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 1.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 1.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 1.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 1.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 1.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 2.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 1.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12, 13 to 17, 18 to 65, and \>65 years. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhea, and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (routine data collection + ADR) within 7 days following vaccination with seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48, 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 7.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 5.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 5.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 8.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 6.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 8.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 5.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 8.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 6.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 2.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 5.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 1.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 1.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 1.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 4.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 4.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 5.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 4.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 10.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 5.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 4.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 10.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 4.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 10.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 4.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 4.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 5.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 3.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 4.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 6.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 4.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 4.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 5.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 5.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 5.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 5.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 5.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 7.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 4.99 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 5.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 5.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 2.96 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 3.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 2.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 2.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 2.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 1.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 1.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 1.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 7.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 4.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 3.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 2.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 2.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 1.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.98 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.95 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 7.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 6.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 4.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 3.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 2.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 2.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 3.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 3.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 3.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 3.74 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 3.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 3.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 11.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 5.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 3.96 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 3.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 4.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 4.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 4.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 4.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 4.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.77 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.81 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.95 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.98 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.70 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.70 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 1.24 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 1.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 1.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 1.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 1.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.71 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 2.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 2.78 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 2.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 2.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 33.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 1.96 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 1.95 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.90 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 1.91 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.91 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.28 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 1.23 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-44 | 0.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-37 | 2.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 4.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-43 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-42 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-38 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-47 | 2.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-41 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-39 | 0.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-48 | 1.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-40 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-40 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 4.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-39 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-41 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-46 | 2.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-38 | 0.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-42 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-47 | 1.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-37 | 1.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-43 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-44 | 0.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-46 | 1.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-48 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-45 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-45 | 1.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-47 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-46 | 0.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-46 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-47 | 0.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-38 | 2.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-45 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-44 | 1.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-44 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-37 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-43 | 0.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-39 | 2.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-45 | 2.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-42 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-40 | 2.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-43 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-41 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-41 | 2.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-38 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-42 | 2.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 6.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-40 | 0.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-43 | 2.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-39 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-39 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-44 | 1.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-37 | 0.93 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-37 | 0.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-45 | 1.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-42 | 1.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-46 | 1.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-44 | 2.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-48 | 1.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-47 | 1.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-41 | 1.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-41 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-43 | 2.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-40 | 1.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-42 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 5.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-39 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-44 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-43 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-38 | 0.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-42 | 2.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-38 | 1.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-45 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 5.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-37 | 2.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-46 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 4.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-48 | 0.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-47 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-41 | 2.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-47 | 0.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-48 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 5.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-46 | 0.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-45 | 0.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 5.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-44 | 0.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-37 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-40 | 2.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-38 | 1.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 5.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-43 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-39 | 1.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-40 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-42 | 0.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-40 | 1.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-39 | 2.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-41 | 0.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-41 | 1.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 4.99 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-40 | 1.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-42 | 1.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-39 | 1.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-43 | 1.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-38 | 2.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-38 | 1.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-44 | 1.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 4.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-37 | 1.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-45 | 1.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-48 | 2.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-46 | 1.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-37 | 3.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-48 | 0.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-47 | 1.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 4.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-47 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-48 | 1.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-48 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-46 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-45 | 0.65 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-43 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 1.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 3.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 3.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 2.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 2.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 2.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 2.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 2.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 2.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 2.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-42 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-43 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-44 | 0.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-45 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-46 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-47 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-48 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-40 | 1.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-41 | 0.74 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-43 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-44 | 0.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-45 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-46 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-47 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-48 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-41 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-43 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-44 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-45 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-46 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-47 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-48 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-39 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-40 | 2.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-41 | 2.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-42 | 1.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-43 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-44 | 1.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-45 | 1.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-46 | 1.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-47 | 1.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-48 | 1.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-41 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-42 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-44 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-45 | 0.20 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-46 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-48 | 0.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-40 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-41 | 0.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-42 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-43 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-45 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-46 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-47 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-48 | 0.30 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-40 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-41 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-42 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-43 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-44 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-45 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-46 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-47 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-48 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-38 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-39 | 0.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-40 | 1.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-41 | 1.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-42 | 1.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-43 | 1.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-44 | 1.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-45 | 1.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-46 | 0.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-47 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-48 | 0.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-36 | 1.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-48 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-47 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.74 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-47 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-46 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-46 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.81 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-43 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-43 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-42 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.79 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-43 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-47 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-44 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-48 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.89 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-46 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-47 | 0.12 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-43 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-47 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-46 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-45 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-41 | 0.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-44 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-42 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.65 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-40 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-41 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-47 | 0.53 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-46 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-42 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-48 | 0.52 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-45 | 0.52 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-44 | 0.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-43 | 0.58 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-42 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-44 | 0.11 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-40 | 0.70 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-39 | 0.64 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-38 | 0.47 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 1.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-45 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-48 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-46 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.89 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-47 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35-48 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35-37 | 0.75 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 4.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 5.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 5.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 5.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 5.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 5.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 6.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 4.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 5.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 5.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 5.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 4.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 4.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 4.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 5.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 4.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 4.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 6.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 4.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 5.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 8.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 6.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 5.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 7.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 2.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 2.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 3.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 1.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 2.78 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 2.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 2.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 2.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 3.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 3.55 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 2.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 2.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 2.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 2.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 7.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 2.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 2.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 1.58 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 1.67 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.60 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.60 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.92 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.78 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.73 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.75 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.77 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 3.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.74 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 1.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 1.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 1.60 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group
SAEs reported here are derived from 2 sources of data - ADR cards and SAEs routinely collected from GPs. SAE data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 1.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.35 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.24 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.31 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group
SAEs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-43 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-44 | 0.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-38 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-45 | 0.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-46 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-47 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-48 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-39 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-40 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-41 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-37 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-42 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-43 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-48 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-45 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-46 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-47 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-42 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-48 | 0.24 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-47 | 0.24 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-37 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-38 | 0.28 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-39 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-40 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-41 | 0.24 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-42 | 0.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-43 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-44 | 0.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-45 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | Week 35-46 | 0.23 Percentage of subjects |
Secondary
Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
SAEs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The cumulative incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any SAEs in EHR (combining routine data collection and card-based ADR reporting system) Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.30 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.24 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 data sources: ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.51 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 2.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 1.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.74 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 1.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 1.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 1.02 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.96 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.91 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 1.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.42 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-44 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-48 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-48 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-43 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-46 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-47 | 0.08 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-38 | 0.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-39 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-40 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-41 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-42 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35-47 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-45 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-46 | 0.09 Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35-35 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35-36 | — Percentage of subjects |
| Unknown | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35-35 | — Percentage of subjects |
Secondary
Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-48 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-37 | 0.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-45 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-38 | 0.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-37 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-39 | 0.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-38 | 0.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-40 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-39 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-46 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-41 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-40 | 0.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-41 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-42 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-41 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-47 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-42 | 0.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-43 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-43 | 0.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-44 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-44 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-43 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-39 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-45 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-46 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-48 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-40 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-47 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-46 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-44 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-48 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-37 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-47 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-38 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.62 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.37 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-41 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-42 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-44 | 0.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-45 | 0.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-46 | 0.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-48 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-43 | 0.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-47 | 0.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-40 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-41 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-42 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-43 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-44 | 0.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-45 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-46 | 0.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-47 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-48 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-48 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-43 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-45 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-46 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-47 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35-48 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-47 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-48 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35-48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-38 | 0.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-39 | 0.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-43 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35-47 | 0.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35-43 | 0.00 Percentage of subjects |
Secondary
Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The cumulative incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Cumulative vaccinated cohort up to the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Cumulative vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine at any point from study start up to end of the week of interest and were registered in EHR (routine data collection \& card-based ADR reporting) during FU period (from vaccination up to 7 days post-vaccination)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 1.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 1.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.47 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.43 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-44 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-45 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-48 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-46 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-47 | 0.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-47 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-45 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-48 | 0.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-46 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-40 | 0.05 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-39 | 0.07 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-41 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-38 | 0.10 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-42 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 35-42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-43 | 0.04 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Cumulative Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35-36 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 6.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 10.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 9.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 11.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 20.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 7.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 9.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 7.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 6.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 10.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 11.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 6.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 5.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 50.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 5.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 7.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 2.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 6.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 5.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 9.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 33.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 5.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 5.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 50.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 7.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 9.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 10.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 11.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 16.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 19.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 2.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 9.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 4.83 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 4.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 2.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 1.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 2.02 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.98 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 11.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 5.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 3.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 10.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 11.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 6.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 7.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 17.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 3.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 7.84 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 7.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 10.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 16.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 7.14 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 8.86 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 6.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 6.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 18.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 5.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 3.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 9.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.91 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 9.38 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.65 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 3.70 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 1.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 6.02 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 1.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 1.59 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 20.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 1.96 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 5.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 3.33 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 1.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 50.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 4.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 2.97 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 1.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 1.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 2.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.40 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 46 | 12.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 45 | 6.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 37 | 15.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 44 | 6.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 38 | 13.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 47 | 6.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 43 | 6.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 45 | 9.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 42 | 5.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 41 | 8.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 41 | 6.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 38 | 9.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 40 | 9.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 42 | 2.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 44 | 4.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 37 | 11.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 43 | 3.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 39 | 9.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 40 | 12.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 46 | 5.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 39 | 13.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 47 | 3.77 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 39 | 2.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 38 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 40 | 7.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 41 | 5.96 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 42 | 2.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 43 | 4.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 44 | 4.80 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 45 | 2.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 47 | 2.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 48 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 40 | 6.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 41 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 46 | 1.07 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 43 | 5.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 44 | 14.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 45 | 4.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 46 | 3.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 47 | 9.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 48 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 37 | 9.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 45 | 2.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 47 | 1.14 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 46 | 3.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 44 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 43 | 1.52 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 37 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 43 | 3.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 42 | 1.89 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 41 | 0.30 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 47 | 4.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 45 | 4.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 40 | 1.72 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 36 | 1.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 44 | 2.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 38 | 1.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | At risk, Week 39 | 2.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 41 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in EHR, by Vaccine Group and United Kingdom Chief Medical Officer (UK CMO)-Specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from General Practitioners (GPs). The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 43 | 6.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 44 | 6.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 45 | 6.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 38 | 10.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 46 | 7.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 47 | 4.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 39 | 10.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 40 | 9.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 41 | 8.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 42 | 5.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 37 | 11.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 43 | 4.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 41 | 5.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 44 | 5.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 39 | 1.89 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 45 | 3.23 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 48 | 5.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 42 | 2.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 46 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 40 | 7.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 47 | 3.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 38 | 10.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 46 | 3.09 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 36 | 1.64 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 37 | 1.28 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 38 | 1.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 39 | 2.26 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 40 | 1.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 41 | 0.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 42 | 1.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 43 | 1.83 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 44 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 45 | 4.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 47 | 1.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Any AEIs Recorded in Electronic Health Record (EHR), by Vaccine Group | Week 35 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 data sources - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years, and \>65 years. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with seasonal influenza vaccine Vaccination of subjects happened between weeks 35 and 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.71 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 2.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 2.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 1.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.49 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.30 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 39 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 43 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 41 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 47 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 37 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 46 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 38 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 40 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 45 | 0.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 41 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 40 | 1.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 44 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 47 | 0.63 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 39 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Fever/pyrexia = all subjects with a fever/pyrexia read code recorded were considered as having fever/pyrexia, regardless of what temperature had been recorded. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 1.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 1.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.59 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 1.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 3.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Fever/Pyrexia Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 1.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 1.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 1.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 1.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 2.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 4.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 1.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 1.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 1.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.62 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.10 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.98 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 16.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 40 | 0.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 2.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 46 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 43 | 20.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 3.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 month to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhoea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 40 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 46 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 39 | 0.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 37 | 0.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 37 | 0.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 39 | 0.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 40 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 41 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 41 | 0.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 46 | 0.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 40 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 44 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 43 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 38 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 42 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 39 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 41 | 0.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 40 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 39 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 2.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 38 | 0.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 37 | 0.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 1.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 45 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 1.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 42 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 38 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 1.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 38 | 1.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 37 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 1.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 44 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 1.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 44 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 45 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 1.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 43 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 43 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 42 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 42 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 41 | 0.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 10.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 40 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 41 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 45 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 45 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 38 | 10 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 45 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 41 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 45 | 0.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 1.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Nausea, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 37 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 43 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Vomiting, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 46 | 1.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Decreased appetite, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group | Diarrhoea, Week 47 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Gastrointestinal adverse events include any gastrointestinal adverse events, decreased appetite, diarrhea, nausea, and vomiting. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 1.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 1.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 1.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 1.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 2.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 1.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 1.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 2.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 2.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 3.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 1.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 2.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 1.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.87 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 1.28 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 3.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Gastrointestinal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 3.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 2.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 2.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 2.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 3.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 2.82 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 1.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 3.76 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 4.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 3.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 4.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 2.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.91 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 1.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 7.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 3.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.98 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 2.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 1.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 9.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 8.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 10.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 4.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.95 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.59 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 45 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 39 | 0.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 41 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 42 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 40 | 0.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 45 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 38 | 0.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 45 | 1.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 37 | 1.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue,Week 46 | 1.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 37 | 4.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 42 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 38 | 3.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue,Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 46 | 1.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 39 | 3.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 40 | 2.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 45 | 1.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 41 | 1.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 44 | 1.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 42 | 1.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 43 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 43 | 2.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 37 | 2.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 42 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 38 | 1.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 43 | 0.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 41 | 0.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 41 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 40 | 1.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 41 | 0.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 40 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 39 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 44 | 1.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 43 | 0.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 38 | 0.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 46 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 37 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 47 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 43 | 1.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 42 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 39 | 1.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 40 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue,Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 44 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 37 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 41 | 1.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 40 | 1.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 38 | 1.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 39 | 1.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 37 | 0.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 40 | 2.34 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 40 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue,Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue,Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 39 | 0.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 41 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 44 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 45 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 41 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 43 | 1.05 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 44 | 1.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 45 | 1.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 40 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 41 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 44 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 41 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 43 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 44 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 45 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue,Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 40 | 1.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 43 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 44 | 0.42 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 40 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 45 | 0.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 37 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 39 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue,Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue,Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 45 | 1.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 45 | 1.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 39 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Headache, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue,Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Irritability, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Malaise, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Fatigue, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group | Drowsiness, Week 47 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. General non-specific symptoms include any general non-specific symptoms, drowsiness, fatigue, headache, irritability, and malaise. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 1.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 1.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 3.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 4.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 2.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 2.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 2.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 3.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 3.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 2.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 4.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 3.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 2.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 5.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 1.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 3.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 2.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.93 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 1.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.45 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 3.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 2.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of General Non-specific Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 3.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 1.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 1.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 2.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 1.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 3.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 1.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 3.08 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 1.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 3.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 2.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 5.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 3.92 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 1.68 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 37 | 1.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 44 | 1.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 45 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 46 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 47 | 1.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 39 | 1.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 40 | 1.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 41 | 1.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 42 | 0.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 38 | 1.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 43 | 0.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 41 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 44 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 45 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 46 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 40 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 43 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 37 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group | Week 35 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Local symptoms include local erythema. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 4.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 1.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 4.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 5.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 3.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 6.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 1.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 1.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 3.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 2.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 1.80 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 1.85 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 1.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 3.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Local Symptoms Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 3.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 5.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 3.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 3.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 2.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 10.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 2.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 2.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 1.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 2.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 2.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 2.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 4.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 1.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 2.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 2.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 3.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 3.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 3.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.91 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 5.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 1.96 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 3.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 2.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 1.22 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 3.13 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 4.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 1.54 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 6.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 1.16 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.49 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 1.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.66 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 45 | 2.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 3.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 37 | 1.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 44 | 1.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 38 | 1.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 44 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 39 | 0.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 43 | 3.01 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 43 | 1.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 40 | 0.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 2.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 42 | 0.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 41 | 0.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 42 | 1.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 1.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 47 | 1.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 41 | 2.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 3.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 4.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 40 | 2.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 1.87 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 39 | 2.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 2.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 46 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 38 | 3.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 1.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 3.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 37 | 3.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 1.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 40 | 0.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 44 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 40 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 44 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 45 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 48 | 2.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 2.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 37 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 38 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 39 | 0.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 1.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 40 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 46 | 2.06 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 38 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Muscle aches / myalgia, Week 43 | 1.22 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Arthropathy, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Musculoskeletal adverse events include any musculoskeletal adverse events, arthropathy, and muscle aches/myalgia. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 2.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 2.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 3.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 3.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 3.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 4.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 2.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 2.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 2.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 2.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 3.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 1.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 1.89 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 5.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 2.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 6.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 4.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 3.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 2.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 4.71 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.96 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 2.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 3.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.93 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.89 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.76 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 2.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 3.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 3.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Musculoskeletal Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.16 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 2.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.65 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 37 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 37 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 44 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 41 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 39 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 38 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 39 | 0.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 40 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 41 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 47 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Bell's palsy, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Guillain-Barre Syndrome, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Peripheral tremor, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 41 | 0.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group | Seizure/Febrile convulsions, Week 47 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Neurological adverse events include any neurological adverse events, Bell's palsy, Guillain-Barre Syndrome, peripheral tremor and seizure/febrile convulsions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 1.50 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.30 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Neurological Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.64 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.90 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.18 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.97 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.93 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 2.56 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 1.40 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.48 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 4.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.53 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.77 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.60 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 1.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 2.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 3.03 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 1.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 1.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.66 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Rash Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported are derived from 2 data sources: ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12, 13 to 17, 18 to 65, and \>65 years. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhea, and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator = the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator = the number of subjects from the denominator who reported any AEIs in EHR (routine data collection + card-based ADR reporting system) within 7 days following vaccination with seasonal influenza vaccine Vaccination happened between weeks 35 and 48, of 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 6.46 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 2.25 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 1.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 2.56 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 2.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 2.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 4.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 33.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 50.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 5.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 4.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 6.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 4.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 2.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 3.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 3.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 1.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 16.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 20.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 7.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 2.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 50.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 6.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 4.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 5.72 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 4.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 4.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 8.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.36 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 6.72 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 6.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 1.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.82 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 5.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 6.90 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 11.11 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 1.59 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 16.67 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 3.38 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 5.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 4.76 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 5.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 3.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 1.39 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 7.81 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 2.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 2.02 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 3.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 5.88 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 1.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 50.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 1.95 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 1.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.68 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 1.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.91 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 3.70 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 4.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 1.59 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 1.96 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.80 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 1.48 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 3.33 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 4.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 4.98 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 4.68 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 2.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 2.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 2.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 40 | 1.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 41 | 1.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 43 | 0.80 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 42 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 45 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 45 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 6.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 5.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 2.52 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 3.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 2.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 37 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 38 | 0.51 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 39 | 0.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 40 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 41 | 0.42 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 42 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 43 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 44 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 37 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 38 | 0.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 39 | 1.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 42 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 43 | 0.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 44 | 0.67 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 45 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 46 | 0.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 47 | 0.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 37 | 2.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 38 | 1.96 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 39 | 2.31 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 40 | 1.65 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 41 | 2.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 42 | 1.10 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 43 | 1.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 44 | 1.33 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 46 | 2.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 47 | 1.55 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 37 | 0.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 38 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 39 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 40 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 41 | 0.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 37 | 1.09 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 38 | 0.83 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 39 | 0.53 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 40 | 0.49 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 41 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 42 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 45 | 0.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 46 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 47 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 44 | 1.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 46 | 1.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 47 | 1.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 37 | 0.93 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 38 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 39 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 40 | 0.63 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 41 | 0.30 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 42 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 43 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 46 | 0.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 47 | 0.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 37 | 2.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 38 | 1.38 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 39 | 1.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 40 | 1.02 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 41 | 1.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 43 | 0.60 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 44 | 0.93 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 45 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 46 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 37 | 3.28 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 38 | 2.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 39 | 2.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 40 | 2.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 41 | 1.92 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 42 | 0.99 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 43 | 2.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 37 | 1.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 38 | 0.91 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 39 | 0.95 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 40 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 41 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 42 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 43 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 47 | 0.39 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 3.61 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 45 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 40 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 39 | 0.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 40 | 2.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 41 | 2.04 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 46 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 43 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 43 | 1.83 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 44 | 2.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 40 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 45 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 46 | 0.35 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 44 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 48 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 45 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 47 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 40 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 43 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 41 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 38 | 10.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 45 | 0.50 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 41 | 1.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 42 | 0.49 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 44 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.73 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 4.09 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 3.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 43 | 1.57 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 2.88 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.69 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 40 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 41 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 41 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 41 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 40 | 1.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 44 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 46 | 0.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 47 | 0.63 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 10.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.94 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 43 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 45 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 1.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 2.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 43 | 0.26 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 40 | 1.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 41 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 43 | 0.79 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 44 | 0.42 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 45 | 0.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 2.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 1.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 36 | 1.64 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 40 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 38 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 39 | 1.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 40 | 0.85 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 42 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 41 | 0.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 1.51 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 42 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 45 | 0.86 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 47 | 1.01 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 44 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Cough, Week 37 | 0.64 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 45 | 0.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 39 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 47 | 0.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.64 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 38 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 42 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Epistaxis, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Coryza, Week 38 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 42 | 0.41 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 1.64 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Oropharyngeal pain, Week 38 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 1.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Nasal congestion, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 44 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.25 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Wheezing, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Conjunctivitis, Week 45 | 0.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Hoarseness, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Rhinorrhoea, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 1.66 Percentage of subjects |
Secondary
Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Respiratory/miscellaneous adverse events include any respiratory/miscellaneous adverse events, conjunctivitis, coryza, cough, epistaxis, hoarseness, nasal congestion, oropharyngeal pain, rhinorrhoea and wheezing. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 3.23 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 6.17 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 4.35 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 6.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 4.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 4.71 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 5.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 4.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 2.79 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 3.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 1.86 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 2.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 8.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 4.85 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 7.94 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 3.43 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 3.66 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 1.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 5.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 6.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 4.15 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 3.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 3.97 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 3.45 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.84 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 2.75 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 3.12 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.32 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 2.44 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 1.46 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 1.19 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 1.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 2.78 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 1.03 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 7.41 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 14.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 2.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 1.34 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 1.15 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 2.55 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.60 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.46 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 1.89 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 3.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 1.69 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 1.74 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 4.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Respiratory/Miscellaneous Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 1.14 Percentage of subjects |
Secondary
Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group
SAEs reported here are derived from 2 sources of data - ADR cards and SAEs routinely collected from GPs. SAE data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.14 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.15 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.73 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 25.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 2.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 1.27 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 1.54 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.61 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.82 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.32 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 2.78 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 3.13 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 3.33 Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group
SAEs reported here are derived from 2 sources of data - ADR cards and SAE routinely collected from GPs. The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any SAEs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 45 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 46 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 39 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 48 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 40 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 37 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 41 | 0.12 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 43 | 0.40 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 38 | 0.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 44 | 0.21 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 45 | 0.25 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 37 | 0.21 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 38 | 0.37 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 40 | 0.17 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 41 | 0.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 44 | 0.36 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 46 | 1.03 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 47 | 0.50 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group | At Week 35 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
SAEs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. The weekly incidence rates of SAEs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any SAEs in EHR (combining routine data collection and card-based ADR reporting system)within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.57 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.74 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.88 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.16 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.33 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.23 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.40 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.19 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.30 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.39 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 1.28 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.57 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 1.56 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of SAEs Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group
AEIs reported here are derived from 2 data sources: ADR cards and AEI routinely collected from GPs. AEI data was presented by age strata: 6 months to 5 years, 6 to 12 years, 13 to 17 years, 18 to 65 years and \>65 years. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between weeks 35 and 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.45 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.36 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.47 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.70 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.81 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.78 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.31 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 1.06 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 3.80 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.52 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 3.17 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 2.53 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 45 | 1.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 38 | 0.27 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | >65 years, Week 47 | 0.00 Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 36 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 - 12 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 18 - 65 years, Week 35 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 6 months to 5 years, Week 38 | — Percentage of subjects |
| Unknown | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine and Age Group | 13 - 17 years, Week 36 | — Percentage of subjects |
Secondary
Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.58 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.41 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 38 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 43 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 39 | 0.05 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 38 | 0.11 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 41 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 41 | 0.06 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.44 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.27 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 37 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 39 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 40 | 0.19 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 46 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 37 | 0.04 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 38 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 44 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 45 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 37 | 0.08 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 39 | 0.07 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 40 | 0.24 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 44 | 0.13 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 44 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 40 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 41 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.58 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 41 | 0.29 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.87 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 38 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 45 | 0.29 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Anaphylactic reactions, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 35 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 38 | 0.18 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Hypersensitivity reactions, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Any, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group | Facial oedema, Week 46 | 0.00 Percentage of subjects |
Secondary
Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status
AEIs reported here are derived from 2 sources of data - ADR cards and AEI routinely collected from GPs. Sensitivity/anaphylaxis adverse events include any sensitivity/anaphylaxis adverse events, anaphylactic reactions, facial edema, and hypersensitivity reactions. The weekly incidence rates of AEIs expressed as the percentage of subjects, were estimated as follows: * The denominator was the number of subjects in the Weekly vaccinated cohort for the week of interest who were registered in EHR (combining routine data collection and card-based ADR reporting system) * The numerator was the number of subjects from the denominator who reported any AEIs in EHR (combining routine data collection and card-based ADR reporting system) within 7 days following vaccination with the seasonal influenza vaccine Vaccination of the subjects happened between week 35 and week 48 of the year 2017
Time frame: Within 7 days post vaccination
Population: Analysis was performed on the Weekly Vaccinated cohort which included all subjects who were vaccinated with a seasonal influenza vaccine during the week of interest and were registered in EHR (combining routine data collection and card-based ADR reporting system) during the safety follow-up period (from vaccination up to 7 days post-vaccination).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.61 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.54 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.22 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.29 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.26 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.34 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.37 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.69 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.48 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.75 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 1.21 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.20 Percentage of subjects |
| Vaccinated_Fluarix Tetra Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 1.18 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.24 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.99 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.28 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 3.70 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.64 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Non GSK Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 38 | 0.20 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 45 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 48 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 36 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 37 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 38 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 39 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 40 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 41 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 42 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 43 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 44 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 45 | 0.43 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 46 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | Not at risk, Week 47 | 0.00 Percentage of subjects |
| Vaccinated_Unknown Brand Group | Weekly Incidence Rates of Sensitivity/Anaphylaxis Adverse Events Recorded in EHR, by Vaccine Group and UK CMO-specified Risk Status | At risk, Week 35 | 0.00 Percentage of subjects |